NightHawk Biosciences to Present at the 4th Annual Treg Directed Therapies Summit on PTX-35
On May 10, 2022, NightHawk Biosciences (NYSE American: NHWK) announced that Dr. Matthew Seavey will present data on PTX-35 at the 4th Annual Treg Directed Therapies Summit from May 17-19 in Boston. PTX-35 is a novel antibody immunomodulator targeting TNFRSF25, currently undergoing Phase 1 trials for solid tumors. The presentation will cover Treg expansion for treating human diseases. The event highlights include showcasing preclinical efficacy and exploring new indications and partnerships for Treg therapies.
- None.
- None.
DURHAM, N.C., May 10, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that Matthew Seavey, Ph.D., MBA, NightHawk’s Vice President of Research will be presenting data on PTX-35, and serving on an expert panel discussing modes of Treg activation, at the 4th Annual Treg Directed Therapies Summit being held on May 17-19th in Boston.
PTX-35 is a novel, potential first-in-class antibody immunomodulator of TNFRSF25 (death receptor 3), a receptor that is preferentially expressed by antigen-experienced T cells and can be utilized to expand regulatory T-cell subsets for auto/inflammatory indications. PTX-35 is the Company's first antibody-based product and is currently in a Phase 1 clinical trial for the treatment of patients with solid tumors.
Presentation Date/Time: Day-1, Wednesday, May 18th at 4:30 PM ET
Presentation Title: Agonizing Over Treg Expansion to Treat Human Disease: An Update on Our TNFRSF25-Agonist, PTX-35
Expert Panel Date/Time: Day-2, Thursday, May 19th at 11:30 AM ET
Expert Panel Title: Optimizing Routes of Administration & Delivery Mechanisms to Induce Timely Treg Specific Activation
Discussion Highlights:
- Describing a clinical-stage Treg immunomodulator with utility in both oncology and auto/inflammation
- Demonstrating preclinical efficacy in several possible, clinical indications including transplantation, autoimmunity, and metabolic diseases
- Expanding plans for new indications and modalities, as well as opportunities for partnerships
The Hanson Wade 4th Annual Treg Directed Therapies Summit is focused on targeting and translating Treg modifying therapies and brings together executives and leading researchers from large pharma, biotech and academia to discuss developments in Treg therapies.
NightHawk Biosciences, Inc.
NightHawk Biosciences is a fully integrated biopharmaceutical company focused on the development of new drugs from discovery through commercialization. The Company leverages its integrated ecosystem of subsidiaries to accelerate the development of novel therapies that arm the immune system, breaking through barriers that prolong traditional drug development. This empowers us to bring our ideas to life with efficient control, superior quality, and uncharacteristic agility.
For more information on the Company and is subsidiaries, please visit: www.nighthawkbio.com, and also follow us on Twitter.
Media and Investor Relations Contact
David Waldman
+1 919 289 4017
investorrelations@heatbio.com
FAQ
What is PTX-35 and its significance for NHWK?
When will NightHawk present at the Treg Directed Therapies Summit?
What topics will be discussed at the Treg Summit involving NHWK?
What is the role of Dr. Matthew Seavey at NightHawk Biosciences?
Where can I find more information about PTX-35 and NightHawk Biosciences?
